Publications

V. Kerestes, J. Kubes, L. Applova, P. Kollarova, O. Lencova-Popelova, I. Melnikova, G. Karabanovich, M. M. Khazeem, H. Bavlovic-Piskackova, P. Sterbova-Kovarikova, C. A. Austin,  J. Roh, M. Sterba, T. Simunek, A. Jirkovska. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Tox. Sci. 2024. accepted (IF₂₀₂₂ = 3.8) (Q_AIS1)

G. Karabanovich, V. Fabiánová, A. Vocat, J. Dušek, L. Valášková, J. Stolaříková, R. R. A. Kitson, P. Pávek, K. Vávrová, K. Djaout, K. Mikušová, A. R. Baulard, S. T. Cole, J. Korduláková, J. Roh*. Both nitro groups are essential for high antitubercular activity of 3,5-dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles through the deazaflavin-dependent nitroreductase activation pathway. J. Med. Chem. 2024, 67, 81-109. (IF₂₀₂₂ = 7.3) (D_AIS1)

V. Finger, T. Kucera, R. Kafkova, L. Muckova, R. Dolezal, J. Kubes, M. Novak, L. Prchal, L. Lakatos, M. Andrs, M. Hympanova, J. Marek, M. Kufa, V. Spiwok, O. Soukup, E. Mezeiova, J. Janousek, L. Nevosadova, M. Benkova, R.R.A. Kitson, M. Kratky, S. Bősze, K. Mikusova, R. Hartkoorn, J. Roh*, J. Korabecny*, 2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1, Eur. J. Med. Chem. 2023, 258, 115611. (IF₂₀₂₂ = 6.7) (Q_AIS1)

P. Hatokova, V. Sestak, H. Bavlovic Piskackova, I. Melnikova, J. Roh, P. Sterbova-Kovarikova. The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products. J. Pharm. Biomed. Anal. 2023, 225, 115220. (IF₂₀₂₁ = 3.571) (Q_AIS2, 3)

V. Finger, M. Kufa, O. Soukup, D. Castagnolo, J. Roh*, J. Korabecny.* Pyrimidine derivatives with antitubercular activity. Eur. J. Med. Chem. 2023, 15(246), 114946. (IF₂₀₂₂ = 6.7) (Q_AIS1)

M. Kopecna, M. Machacek, J. Roh, K. Vavrova. Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers. Sci. Rep. 2022, 12(1), 19495. (IF₂₀₂₁ = 4.997) (Q_AIS2)

L. Gorecki, D. Muthna, S. Merdita, M. Andrs, T. Kucera, R. Havelek, L. Muckova, T. Kobrlova, J. Soukup, P. Krupa, L. Prchal, O. Soukup, J. Roh, M. Rezacova, J. Korabecny. 7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties. Eur. J. Med. Chem. 2022, 240, 114580. (IF₂₀₂₁ = 7.088) (Q_AIS1)

P. Haskova, L. Applova, H. Jansova, P. Homola, K. J. Franz, K. Vavrova, J. Roh, T. Simunek. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Sci. Rep. 2022, 12, 9765. (IF₂₀₂₁ = 4.997) (Q_AIS2)

E. Jirkovský, A. Jirkovská, H. Bavlovič-Piskáčková, V. Skalická, Z. Pokorná, G. Karabanovich, P. Kollárová-Brázdová, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, A. R. Lyon, J. Roh, T. Šimůnek, P. Štěrbová-Kovaříková, M. Štěrba. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail. 2021;14: e008209. (IF₂₀₂₁ = 10.447) (D_AIS1)

P. Kollárová-Brázdová, O. Lencova-Popelova, G. Karabanovich; J. Kocúrová-Lengvarská, J. Kubes, N. Váňová, Y. Mazurova, M. Adamcova, A. Jirkovska, M. Holečková, T. Šimůnek, P. Štěrbová-Kovaříková, J. Roh, M. Štěrba. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity on a rabbit model in vivo. Clin. Sci. 2021. 135, 1897–1914. (IF₂₀₂₁ = 6.876) (Q_AIS1)

A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, C. A. Austin, T. Šimůnek, J. Roh*. Structure−Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J. Med. Chem. 2021, 64, 3997-4019. (IF₂₀₂₁ = 8.039) (D_AIS1)

H. Bavlovič Piskáčková, H. Jansová, J. Kubeš, G. Karabanovich, N. Váňová, P. Kollárová-Brázdová, I. Melnikova, A. Jirkovská, O. Lenčová-Popelová, J. Chládek, J. Roh, T. Šimůnek, M. Štěrba, P. Štěrbová-Kovaříková. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF 193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports. 2021 11, 4456. (IF₂₀₂₁ = 4.996) (Q_AIS2)

N. Monakhova, J. Kordulakova, A. Vocat, A. Egorova, A. Lepioshkin, E. G. Salina, J. Nosek, E. Repkova, J. Zemanova, H. Jurdakova, R. Gorova, J. Roh, G. Degiacomi, J. C. Sammartino, M. R. Pasca, S. T. Cole, K. Mikusova, V. Makarov. Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity. ACS Infect. Dis. 2021, 7(1), 88-100. (IF₂₀₂₁ = 5.578) (D_AIS1)

P. Kollárová-Brázdová, A. Jirkovská, G. Karabanovich, Z. Pokorná, H. Bavlovič Piskáčková, E. Jirkovský, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, V. Skalická, P. Štěrbová-Kovaříková, J. Roh, T. Šimůnek and M. Štěrba. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics 2020, 373(3), 402-415. (IF₂₀₂₀ = 4.030)  (Q_AIS1)

M. Kopecna, M. Machacek, A. Novackova, G. Paraskevopoulos, J. Roh, K. Vavrova. Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers. Sci. Rep. 2019, 9, 14617. (IF₂₀₁₉ = 3.998) (Q1)

G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh*. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019,62, 8115-8139. (IF₂₀₁₉ = 6.205) (Q1)

P. Reimerova; J. Stariat, H. Piskackova, H. Jansova, J. Roh, D.S. Kalinowski, M. Machacek, T. Simunek, D. R. Richardson, P. Sterbova-Kovarikova. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal. Bioanal. Chem. 2019, 411(11), 2383-2394. (IF₂₀₁₉ = 3.637) (Q1)

P. Reimerova, A. Jirkovska, H. Piskackova, G. Karabanovich, J. Roh, T. Simunek, P. Sterbova-Kovarikova. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.  Sci. Rep. 2019, 9, Art. No. 4524. (IF₂₀₁₉ = 3.998) (Q1)

H. Jansová, J. Kubeš, P. Reimerová, P. Štěrbová-Kovaříková, J. Roh*, and T. Šimůnek.* 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chem. Res. Toxicol., 2018, 31 (11), 1151–1163. (IF₂₀₁₈ = 3.274)

E. Jirkovský, A. Jirkovská, J. Bureš, J. Chládek, O. Lenčová, J. Stariat, Z. Pokorná, G. Karabanovich, J. Roh, P. Brázdová, T. Šimůnek, P. Kovaříková, M. Štěrba. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. Journal of Pharmacology and Experimental Therapeutics. 2018, 364 (3), 433-446. (IF₂₀₁₈ = 3.615) (Q1)

J. Bureš, A. Jirkovská, V. Šesták, H. Jansová, G. Karabanovich, J. Roh, M. Štěrba, T. Šimůnek, P. Kovaříková. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology 2017, 392, 1-10. (IF₂₀₁₇ = 3.265)

I. Melnikova, J. Roh, J. Kuneš, T. Artamonova, Y. Zevatskii, L. Myznikov. Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers. Tetrahedron Lett. 2017, 58, 3842–3845. (IF₂₀₁₇ = 2.125)

J. Roh *, G. Karabanovich, H. Vlčková, A. Carazo, J. Němeček, P. Sychra, L. Valášková, O. Pavliš, J. Stolaříková, V. Klimešová, K. Vávrová, P. Pávek, A. Hrabálek. Development of Water-Soluble 3,5-Dinitrophenyl Tetrazole and Oxadiazole Antitubercular Agents. Bioorg. Med. Chem. 2017, 25, 5468–5476. (IF₂₀₁₇ = 2.881)

E. Mezeiova, J. Korabecny, V. Sepsova, M. Hrabinova, P. Jost, L. Muckova, T. Kucera, R. Dolezal, J. Misik, K. Spilovska, N. L. Pham, L. Pokrievkova, J. Roh, D. Jun, O. Soukup, D. Kaping, K. Kuca. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy. Molecules 2017, 22, 1265. (IF₂₀₁₇ = 3.098)

J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh,* V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF₂₀₁₇ = 4.816) (Q1)

G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh,* V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF₂₀₁₇ = 4.816) (Q1)

J. Roh,* G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588. (IF₂₀₁₆ = 2.650)

A. Kováčik, L. Opálka, M. Šilarová, J. Roh, K. Vávrová. Synthesis of 6-hydroxyceramide using rutheniumcatalyzed hydrosilylation–protodesilylation. Unexpected formation of a long periodicity lamellar phase in skin lipid membranes. RSC Advances, 2016, 6, 73343–73350. (IF₂₀₁₆ = 3.108)

H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24. (IF₂₀₁₆ = 3.582) (Q1)

V. Sestak , J. Roh, L. Klepalova, P. Kovarikova. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, A Novel Proteasome Inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 365–373. (IF₂₀₁₆ = 3.255) (Q1)

G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh.* Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF₂₀₁₆ = 6.259) (Q1)

L. Lochman, J. Svec, J. Roh, K. Kirakci, K. Lang, P. Zimcik, V. Novakova. Metal-Cation Recognition in Water by a Tetrapyrazinoporphyrazine-Based Tweezer Receptor. Chem. Eur. J., 2016, 22(7), 2417-2426. (IF₂₀₁₆ = 5.317) (Q1)

V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6 (40), 42411-42428. (IF₂₀₁₆ = 5.168) (Q1)

L. Opálka, A. Kováčik, M. Sochorová, J. Roh, J. Kuneš, J. Lenčo, K. Vávrová. Scalable Synthesis of Human Ultralong Chain Ceramides. Org. Lett., 2015, 17 (21), 5456–5459. (IF₂₀₁₅ = 6.732) (Q1)

E. Potůčková, J. Roh, M. Macháček, S. Sahni, J. Stariat, V. Šesták, H. Jansová, P. Hašková, A. Jirkovská, K. Vávrová, P. Kovaříková, D. S. Kalinowski, D. R. Richardson, T. Šimůnek. In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE 2015, 10 (10). e0139929. (IF₂₀₁₅ = 3.057) (Q1)

A. Jirkovska, J. Roh, O. Lenčová-Popelová, E. Jirkovsky, K. Hruskova, E. Potuckova, H. Jansova, P. Haskova, P. Martinkova, T. Eisner, M. Kratochvil, J. Sus, M. Machacek, L. Tichotova, V. Gersl, D. S. Kalinowski, M. Muller, D. Richardson, K. Vavrova, M. Sterba, T. Simunek. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol. Res. 2015, 4, 1098–1114. (IF₂₀₁₅ = 2.161)

L. Lochman, J. Svec, J. Roh, V. Novakova. The role of the size of aza-crown recognition moiety in azaphthalocyanine fluorescence sensors for alkali and alkaline earth metal cations. Dyes Pigment. 2015, 121, 178-187. (IF₂₀₁₅ = 4.055) (Q1)

G. Karabanovich, J. Roh,* O. Soukup, I. Pávková, M. Pasdiorová, V. Tambor, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek. Tetrazole Regioisomers in the Development of Nitro Group-Containing Antitubercular Agents. Med. Chem. Commun. 2015, 6, 174-181. (IF₂₀₁₅ = 2.319)

B. Skolova, K. Hudska, P. Pullmannova, A. Kovacik, K. Palat, J. Roh, J. Fleddermann, I. Estrela-Lopis, K. Vavrova. Different Phase Behavior and Packing of Ceramides with Long (C16) and Very Long (C24) Acyls in Model Membranes: Infrared Spectroscopy Using Deuterated Lipids. J. Phys. Chem. B 2014, 118 (35), 10460-10470. (IF₂₀₁₄ = 3.302)

G. Karabanovich, J. Roh,* T. Smutný, J. Něměcek, P. Vicherek, J. Stolaříková, M. Vejsová, I. Dufková, K. Vávrová, P. Pávek, V. Klimešová, A. Hrabálek. 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. Eur. J. Med. Chem. 2014, 82, 324-340. (IF₂₀₁₄ = 3.447) (Q1)

A. Kovacik, J. Roh, K. Vavrova. The Chemistry and Biology of 6-Hydroxyceramide, the Youngest Member of the Human Sphingolipid Family. ChemBioChem 2014, 15 (11), 1555-1562. (IF₂₀₁₄ = 3.088)

B. Skolova, K. Jandovska, P. Pullmannova, O. Tesar, J. Roh, A. Hrabalek, K. Vavrova. The Role of the Trans Double Bond in Skin Barrier Sphingolipids: Permeability and Infrared Spectroscopic Study of Model Ceramide and Dihydroceramide Membranes. Langmuir 2014, 30 (19), 5527-5535. (IF₂₀₁₄ = 4.457) (Q1)

J. Stariat, V. Suprunova, J. Roh, V. Sestak, T. Eisner, T. Filipsky, P. Mladenka, M. Nobilis, T. Simunek, J. Klimes, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomed. Chromatogr. 2014, 28 (5), 621-629. (IF₂₀₁₄ = 1.723)

D. Diblikova, M. Kopecna, B. Skolova, M. Krecmerova, J. Roh, A. Hrabalek, K. Vavrova. Transdermal Delivery and Cutaneous Targeting of Antivirals using a Penetration Enhancer and Lysolipid Prodrugs. Pharm. Res. 2014, 31 (4), 1071-1081. (IF₂₀₁₄ = 3.420) (Q1)

B. Školová, B. Janůšová, J. Zbytovská, G. Gooris, J. A. Bouwstra, P. Slepička, P. Berka, J. Roh, K. Palát, A. Hrabálek, K. Vávrová. Ceramides in the Skin Lipid Membranes: Length Matters. Langmuir 2013, 29, 15624-15633. (IF₂₀₁₃ = 4.384) (Q1)

G. Karabanovich, J. Roh,* Z. Padělková, Z. Novák, K. Vávrová, A. Hrabálek, One-pot synthesis of 1-substituted-5-alkylselanyl-1H-tetrazoles from isoselenocyanates: Unexpected formation of N-alkyl-N-arylcyanamides and (Z)-Se-alkyl-N-cyano-N,N’-diarylisoselenoureas. Tetrahedron 2013, 69, 8798-8808. (IF₂₀₁₃ = 2.817)

L. Myznikov, U. Dmitrieva, T. Artamonova, J. Roh, A. Hrabálek, Y. Zevatskii, An Efficient Synthesis of 1-Substituted 5-Bromo-1H-tetrazoles. Synthesis 2013, 45, 2029-2033. (IF₂₀₁₃ =2.443)

B. Janůšová, B. Školová, K. Tükörová, L. Wojnarová, T. Šimůnek, P. Mladěnka, T. Filipský, M. Říha, J. Roh, K. Palát, A. Hrabálek, K. Vávrová, Amino acid derivatives as transdermal permeation enhancers. J. Control. Release 2013, 165 (2), 91-100. (IF₂₀₁₃ = 7.261) (Q1)

J. Roh,* K. Vavrova, A. Hrabalek, Synthesis and Functionalization of 5-Substituted Tetrazoles, Eur. J. Org. Chem., 2012, 6101–6118. (IF₂₀₁₂ = 3.344) (Q1)

V. Novakova, J. Roh, P. Gela, J. Kuneš, P. Zimcik, Azaphthalocyanines with fused triazolo rings: formation of sterically stressed constitutional isomers. Chem. Commun. 2012, 48, 4326-4328. (IF₂₀₁₂ = 6.378) (Q1)

K. Vávrová, P. Kovaříková, B. Školová, M. Líbalová, J. Roh, R. Čáp, A. Holý, A. Hrabálek, Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr‑PMEDAP. Pharm. Res. 2011; 28 (12), 3105-3115. (IF₂₀₁₁ = 4.093) (Q1)

J. Roh,* K. Vávrová, A. Hrabálek. One-pot regioselective vinylation of tetrazoles: preparation of 5-substituted 2-vinyl-2H-tetrazoles. Tetrahedron Lett. 2010, 51 (10), 1411–1414. (IF₂₀₁₀ = 2.618)

J. Roh,* T. V. Artamonova, K. Vávrová, G. I. Koldobskii, A. Hrabálek, Practical Synthesis of 5-Substituted Tetrazoles under Microwave Irradiation. Synthesis 2009, (13), 2175-2178. (IF₂₀₀₉ = 2.572)